Alendronate sodium has helped prevent and treat osteoporosis in postmenopausal women since 1995. For many years, it has been prescribed by doctors to build bone and protect from fractures at the hip and spine.
Fosamax® was the branded alendronate sodium approved by the US Food and Drug Administration (FDA) as being safe and effective. Generic alendronate sodium products became available to patients over time with the same alendronate sodium to help prevent and treat osteoporosis. Both Fosamax and the generic versions of the drug are available in a tablet that must be taken with 8 oz of water. Other conditions of use apply.
The next generation of osteoporosis therapy is available with BINOSTO® (alendronate sodium) effervescent tablet for oral solution 70 mg. BINOSTO, once dissolved in 4 oz of water, forms a buffered effervescent solution. It is taken once weekly. The FDA approved BINOSTO and found it to be bioequivalent to Fosamax1, which means it works the same way.
The additional benefit is that BINOSTO is not a tablet that you swallow whole. It is an effervescent tablet that dissolves completely in water to become a strawberry-flavored, buffered solution.
Before BINOSTO became available, chances are that a woman's difficulty swallowing pills resulted in her not taking the medicine her doctor prescribed. That can have serious consequences since osteoporosis can shorten patients’ lives if untreated, with heightened risks of bone fractures.
BINOSTO is the first and only prescription medicine for postmenopausal women diagnosed with osteoporosis that gives you proven fracture protection in a buffered, effervescent solution. It is a treatment option when tablets just aren't the right choice--for any reason.
Fosamax is a registered trademark of Merck & Co., Inc.
1. BINOSTO Prescribing Information, Mission Pharmacal Company.